Mylan Settles With Cephalon Over Provigil Generics
This article was originally published in The Pink Sheet Daily
Cephalon has reached a settlement with the third of four companies involved in a patent litigation suit over Cephalon's sleep disorder treatment Provigil (modafinil), the company announced Jan. 10
You may also be interested in...
Barr could gain up to two months of exclusivity for its Actiq generic.
Nearly two weeks after settling with Teva, Cephalon has reached a settlement with Ranbaxy that is identical to Teva's deal for generic modafinil.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.